Critical analysis of molecular tests in indeterminate thyroid nodules

WHICH TEST SHOULD BE CHOSEN? Only a few institutions reported their experience and compared the performance of molecular tests in similar conditions. In one of them, two-thirds of Bethesda categories III and IV lesions were managed nonoperatively based on nonsuspicious results of Thyroseq® v2 or Afirma® GEC. Considering the rate of malignancy of 14%, Livhits and cols. () demonstrated that ThyroSeq® v.2 had a better performance to identify malignancy compared to GEC (PPV 57% vs. 39%). Similarly, Jug and cols. [...]